RxDoctor Payments Data

Richard Park, MD

Internal Medicine · Granada Hills, CANPI 1174718134

Payments from drug & device makers

$608,479in general payments, 2019–2025

Across 66 payments — averaging $9219.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acella Pharmaceuticals, LLC$222K
  • AstraZeneca$212K
  • Cleerly, Inc.$122K
  • Alnylam Pharmaceuticals Inc.$24K
  • Avion Pharmaceuticals$16K
  • BD$12K
  • plus $726 from 11 others

What the payments were for

  • Food & beverage$726100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$608,479 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$22,705,869
Medicare patients
4,426
Services billed
67,859

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase32$29,570
TradjentaLinagliptin22$22,661
JanuviaSitagliptin Phosphate22$20,707
FarxigaDapagliflozin Propanediol26$18,744
MyrbetriqMirabegron30$18,326
JardianceEmpagliflozin21$16,972
VascepaIcosapent Ethyl25$14,945
OzempicSemaglutide11$14,876
JanumetSitagliptin Phos/Metformin Hcl14$14,532
LinzessLinaclotide16$12,991
TrulicityDulaglutide11$10,534
EliquisApixaban13$9,707
Diclofenac Sodium25$5,994
Icosapent Ethyl21$4,554
Celecoxib40$2,753

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$35$42,56148 claims
AstraZenecaFarxiga$211,738$18,74426 claims
Novo NordiskOzempic$26$14,87611 claims
Lilly USA, LLCTrulicity$55$10,53411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Granada Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →